CompletedPhase 2NCT00939809
A6 in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
Studying Primary peritoneal carcinoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Gynecologic Oncology Group
- Principal Investigator
- Michael GoldGynecologic Oncology Group
- Intervention
- Urokinase-Derived Peptide A6(biological)
- Enrollment
- 31 enrolled
- Eligibility
- 18 years · FEMALE
- Timeline
- 2009
Study locations (16)
- Georgia Regents University Medical Center, Augusta, Georgia, United States
- University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States
- Nebraska Methodist Hospital, Omaha, Nebraska, United States
- Stony Brook University Medical Center, Stony Brook, New York, United States
- Case Western Reserve University, Cleveland, Ohio, United States
- MetroHealth Medical Center, Cleveland, Ohio, United States
- Cleveland Clinic Cancer Center/Fairview Hospital, Cleveland, Ohio, United States
- Riverside Methodist Hospital, Columbus, Ohio, United States
- Hillcrest Hospital Cancer Center, Mayfield Heights, Ohio, United States
- University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States
- Abington Memorial Hospital, Abington, Pennsylvania, United States
- Magee-Womens Hospital of UPMC, Pittsburgh, Pennsylvania, United States
- Women and Infants Hospital, Providence, Rhode Island, United States
- Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States
- Huntsman Cancer Institute/University of Utah, Salt Lake City, Utah, United States
- +1 more locations on ClinicalTrials.gov
Collaborators
National Cancer Institute (NCI)
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00939809 on ClinicalTrials.govOther trials for Primary peritoneal carcinoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1, PHASE2NCT07480954Dual-Targeting CAR-NK Cells for Recurrent Ovarian Cancer (MSLN, FRα, MUC16)Beijing Biotech
- RECRUITINGPHASE1, PHASE2NCT07322094CATALINA-4: A Study to Investigate the Safety and Efficacy of TORL-1-23 With Chemotherapy Given Before Initial Surgery in Women With Advanced Stage Ovarian CancerTORL Biotherapeutics, LLC
- RECRUITINGPHASE3NCT06915025Phase 3 Trial Evaluating the Safety & Efficacy of IMNN-001 Administered in Combination w/ Standard NACT & Adjuvant Chemotherapy in Newly Diagnosed Patients w/ Advanced EOC, Fallopian Tube or Primary Peritoneal CancerImunon
- RECRUITINGPHASE2NCT07023484Personalized Timing of Interval Debulking Surgery in Advanced Ovarian CancerThe University of Hong Kong
- RECRUITINGPHASE2NCT06639074Folate Receptor Alpha Dendritic Cells (FRαDCs) or Placebo for the Treatment of Patients With Stage III or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer, FAROUT TrialMayo Clinic
- RECRUITINGPHASE1NCT06469281A Study to Learn if 27T51, a Mucin-16 (MUC16) Protein Targeting Immune Cell Therapy, Administered Alone or in Combination is Safe and How Well it Works for Adult Participants With Recurrent or Treatment Resistant Ovarian CancersRegeneron Pharmaceuticals
- RECRUITINGPHASE2NCT06492070Cryocompression With or Without Cilostazol for the Prevention of Paclitaxel-induced Neuropathy in Patients With Gynecological CancersEmory University
- RECRUITINGPHASE2NCT06434610A Study of B013 in Combination With Paclitaxel in Patients With Platinum-resistant Recurrent Ovarian Cancer.Shanghai Jiaolian Drug Research and Development Co., Ltd